Cellebrite DI (NASDAQ:CLBT) Price Target Lowered to $18.00 at Needham & Company LLC

Key Points

• Needham & Company LLC has lowered its target price for Cellebrite DI (NASDAQ:CLBT) from $24.00 to $18.00, maintaining a "buy" rating which suggests a potential upside of 16.58% from its current price.
• In addition to Needham, Wall Street Zen has downgraded the stock from a "buy" to a "hold" rating, indicating mixed analyst sentiment about Cellebrite DI's future performance.
• Cellebrite DI reported a quarterly earnings per share of $0.12, slightly beating analysts' expectations, with revenues increasing by 18.4% compared to the same quarter last year.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) had its target price dropped by analysts at Needham & Company LLC from $24.00 to $18.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. Needham & Company LLC's target price points to a potential upside of 13.92% from the stock's current price.

Other research analysts have also issued reports about the stock. JPMorgan Chase & Co. dropped their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Wall Street Zen downgraded shares of Cellebrite DI from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $22.40.

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock traded down $0.36 during trading on Thursday, hitting $15.80. The company's stock had a trading volume of 2,576,424 shares, compared to its average volume of 2,298,287. The company has a fifty day simple moving average of $14.96 and a two-hundred day simple moving average of $17.67. The company has a market capitalization of $3.78 billion, a PE ratio of 47.53, a P/E/G ratio of 3.20 and a beta of 1.27. Cellebrite DI has a 52 week low of $13.10 and a 52 week high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.01. The firm had revenue of $113.28 million for the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The business's quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts predict that Cellebrite DI will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CLBT. Axon Enterprise Inc. acquired a new position in Cellebrite DI during the fourth quarter worth $198,270,000. T. Rowe Price Investment Management Inc. acquired a new stake in Cellebrite DI during the first quarter worth about $60,939,000. Invesco Ltd. grew its stake in Cellebrite DI by 122.1% during the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after purchasing an additional 1,811,757 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in Cellebrite DI by 749.9% during the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock worth $29,508,000 after buying an additional 1,340,000 shares during the last quarter. Finally, Voss Capital LP lifted its holdings in shares of Cellebrite DI by 34.0% in the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company's stock worth $82,400,000 after purchasing an additional 1,306,398 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.